In this interview series called, “5 Things Everyone Needs To Know About Cancer” we are talking to experts about cancer such as oncologists, researchers, and medical directors to address these questions.
Carisma Therapeutics is making waves again with its recent news that it has been granted Fast Track Designation by the FDA to its CT-0508 for the treatment of patients with solid tumors.
The FDA has granted fast track designation to the HER2-targeted chimeric antigen receptor-macrophage (CAR-M), CT-0508, for the treatment of patients with solid tumors, announced Carisma Therapeutics, Inc.
The FDA granted fast track designation to CT-0508 for treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2. CT-0508 (Carisma Therapeutics) is an autologous, gene-edited chimeric antigen receptor...